SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending due to an earnings "double beat" and positive AI demand commentary, fueling optimism and sending shares higher after hours. The community is celebrating the results, anticipating further gains, and some speculate about government influence and potential short squeezes. Discussions include targets, the CEO's performance, and the broader implications for the semiconductor sector.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum ($QBTS) is trending amid speculation and conflicting reports about potential government equity stakes in quantum computing firms, driving volatility and high trading volume. The community is debating the validity and impact of the rumored deal, with some seeing it as a validation of the sector while others believe it's a pump and dump scheme. Broader discussions include the long-term potential of quantum computing and its significance in the global technology race.

Ford Motor Co. engages in the manufacture, distribution, and sale of automobiles. It operates through the following segments: Ford Blue, Ford Model E, Ford Pro, Ford Next, Ford Credit, and Corporate Other. The Ford Blue, Ford Model E, and Ford Pro segment includes the sale of Ford and Lincoln vehicles, service parts, and accessories, together with the associated costs to develop, manufacture, distribute, and service the vehicles, parts, and accessories. The Ford Next segment is involved in the expenses and investments for emerging business initiatives aimed at creating value for Ford in vehicle-adjacent market segments. The Ford Credit segment consists of the Ford Credit business on a consolidated basis, which is primarily vehicle-related financing and leasing activities. The Corporate Other segment refers to corporate governance expenses, past service pension and OPEB income and expense, interest income and gains and losses from cash, cash equivalents, and marketable securities, and foreign exchange derivatives gains, and losses associated with intercompany lending. The company was founded by Henry Ford on June 16, 1903 and is headquartered in Dearborn, MI.

Ford Motor Co.

Ford Motor Co

Ford ($F) is trending as investors react to potential tariff relief and strong Q3 sales figures, including a surge in EV sales, before the EV tax credit expires. Community members are discussing whether Ford can sustain this momentum, especially with a focus on management's plans and the potential for a breakout above the $12.50 resistance level. Some are also closely monitoring a news report regarding potential changes coming Monday.

Deckers Outdoor Corp. engages in the business of designing, marketing, and distributing footwear, apparel, and accessories developed for both everyday casual lifestyle use and high performance activities. It operates through the following segments: UGG Brand, HOKA Brand, Teva Brand, Sanuk Brand, Other Brands, and Direct-to-Consumer. The UGG Brand segment offers a line of premium footwear, apparel, and accessories. The HOKA Brand segment sells footwear and apparel that offers enhanced cushioning and inherent stability with minimal weight, originally designed for ultra-runners. The Teva Brand segment focuses on the sport sandal and modern outdoor lifestyle category, such as sandals, shoes, and boots. The Sanuk Brand segment originated in Southern California surf culture and has emerged into a lifestyle brand with a presence in the relaxed casual shoe and sandal categories. The Other Brands segment includes the Koolaburra by UGG brand. The Direct-to-Consumer segment consists of retail stores and e-commerce websites. The company was founded by Douglas B. Otto in 1973 and is headquartered in Goleta, CA.

Deckers Outdoor Corp.

Deckers Outdoor (DECK) is experiencing share price volatility despite a recent earnings beat, leading to community discussion about potential reasons for the disconnect, including concerns about future guidance. Some traders point to significant call option activity, while others speculate on the impact of tariffs and broader retail sector trends. Despite strong brand performance with Hoka and UGG, investors are debating whether the current price represents a buying opportunity or reflects deeper concerns.

Newmont Corp. engages in the exploration and acquisition of gold properties, containing copper, silver, lead, zinc or other metals. It operates through the following geographical segments: Canada, Mexico, Suriname, Argentina, Peru, Australia, Papua New Guinea, Ghana, and U.S. The company was founded by William Boyce Thompson on May 2, 1921 and is headquartered in Denver, CO.

Newmont Corp

Newmont Corp ($NEM) is trending after posting strong quarterly earnings, exceeding analysts' estimates, which the community is calling a major beat. Bullish sentiment is growing as investors discuss cost-saving initiatives and rising gold prices potentially driving the stock higher. However, some traders are cautious, anticipating short-term pullbacks and profit-taking despite the positive results.

Lumen Technologies, Inc. is an investment holding company, which engages in the provision of integrated communications to residential and business customers. It operates through the Business and Mass Markets segments. The Business segment provides products and services under four sales channels to enterprise and commercial customers. The Mass Markets segment focuses on consumer and small business customers. The company was founded in 1930 and is headquartered in Monroe, LA.

Lumen Technologies Inc

Lumen is trending following news of a multi-billion dollar network expansion aimed at meeting growing AI demand. Community members are discussing the potential for increased revenue, key partnerships, and upcoming earnings while also debating the company's debt and long-term growth strategy. Some are speculating about new deals and the possibility of a short squeeze, while others highlight the company's strategic importance in the AI infrastructure buildout.

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002 by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in New York, NY.

Teladoc Health Inc

Teladoc is trending as investors discuss the potential impact of CFO Mala Murthy's departure, with many viewing it as a positive catalyst for the stock. Community members are also focused on upcoming earnings and the company's AI applications, speculating on a possible short squeeze. Overall sentiment suggests optimism about a turnaround, with some drawing comparisons to other heavily shorted stocks.

Above Food Ingredients, Inc. engages in operating its subsidiaries, Bite Acquisition Corp. (Bite) and Above Food Corp. (Above Food). The Bite is a blank check company that affects a merger, stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The Above Food is an ingredient company that provides food products and brands. The company was founded by Lionel Kambeitz on April 18, 2023 and is headquartered in Regina, Canada.

Above Food Ingredients Inc.

ABVE is trending as investors eagerly await news related to the Palm Global merger and the audit results, with some speculating about potential catalysts at upcoming conferences. Community members are expressing both excitement and impatience, while also debating short selling activity and potential price targets. The anticipation surrounds the company's transition towards real-world asset tokenization and stablecoin issuance.

Uber Technologies, Inc. is a technology platform, which engages in the development and operation of technology applications, networks, and product to power movement from point A to point B. The firm offers ride services and merchants delivery service providers for meal preparation, grocery, and other delivery services. It operates through the following segments: Mobility, Delivery, and Freight. The Mobility segment refers to products that connect consumers with Mobility Drivers who provide rides in a variety of vehicles, such as cars, auto rickshaws, motorbikes, minibuses, or taxis. The Delivery segment offers consumers the chance to search for and discover local restaurants, order a meal, and either pick-up at the restaurant or have the meal delivered. The Freight segment focuses on connecting Carriers with Shippers on its platform, and gives Carriers upfront, transparent pricing, and the ability to book a shipment. The company was founded by Oscar Salazar Gaitan, Travis Kalanick, and Garrett Camp in 2009 and is headquartered in San Francisco, CA.

Uber Technologies Inc

Uber's stock is trending amid news of a collaboration with Nvidia to advance autonomous vehicle technology, sparking discussions about the company's strategic position and potential revenue streams in the evolving transportation sector; the community is analyzing the partnership's impact, especially in light of Uber's existing partnerships with EV manufacturers like Lucid and potential competition with Tesla. Some investors believe this could drive significant growth, while others express concern about immediate revenue impact and the stock's historical resistance to meaningful gains on news.

Ventyx Biosciences, Inc. engages in developing novel small molecule therapeutics for the treatment of autoimmune diseases. Its clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1-ready peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. The company was founded by Raju S. Mohan on November 21, 2018 and is headquartered in San Diego, CA.

Ventyx Biosciences Inc

Ventyx Biosciences ($VTYX) is trending due to recent Phase 2 trial results, sparking discussions around the drug's potential in treating obesity and cardiovascular risk factors. While some traders are optimistic about potential analyst upgrades and a possible buyout, others express concerns about a potential offering. Community members are actively debating entry and exit points, as well as speculating on future price movements and consolidation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Maze Therapeutics, Inc. (MAZE) on Thursday announced that it has entered into a securities purchase agreement for the private placement of its securities for gross proceeds of about $150 million. Shares of the company soared 56% in the pre-market session at the time of writing.The <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.mazetx.com/news-releases/news-release-details/maze-therapeutics-announces-oversubscribed-1500-million-private">private placement</a> involves the sale of over four million shares of common stock at $16.25 &nbsp;apiece, implying a premium of over 1% from the stock’s closing price on Wednesday. The placement is expected to close on September 12, the company said, while adding that both new and existing investors will participate.The firm said that the private placement includes participation from Frazier Life Sciences, Deep Track Capital, Driehaus Capital Management, Janus Henderson Investors, Logos Capital, TCGX, and Venrock Healthcare Capital Partners, as well as other healthcare-dedicated funds.The South San Francisco-based biopharmaceutical company is developing medicines for patients with kidney and metabolic diseases. It stated that it expects to utilize the proceeds from the placement to advance the development of MZE829 in patients with APOL1-mediated kidney disease, initiate mid-stage clinical trials of MZE782 in both phenylketonuria (PKU) and chronic kidney disease (CKD), and continue progress on its research and discovery programs. The company also intends to use the funds for working capital and other general corporate purposes.Last month, the company said that it ended June with cash and cash equivalents of $264.5 million, which it expects will fund operations into the second half of 2027.Separately, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.mazetx.com/news-releases/news-release-details/maze-therapeutics-announces-positive-first-human-results-phase-1">also</a> announced positive clinical results from an early-stage study of MZE782, including “an excellent safety profile, robust target engagement and compelling pharmacodynamic effects.” The firm stated that the study data in 112 healthy volunteers exceeded expectations, enabling mid-stage advancement in the treatment of both PKU and CKD in 2026.Maze went public in January. The stock is up by 0.4% since its listing.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/bitcoin-in-consolidation-mike-novogratz-sees-solana-ethereum-taking-spotlight/chwN1oPRdvg">‘Bitcoin in Consolidation’ – Galaxy’s Mike Novogratz Reportedly Sees Solana, Ethereum Taking Spotlight For Now</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Maze Therapeutics Stock Just Shot Up 56% Pre-Market Today – Here’s What Happened

The company announced a private placement for over four million shares of common stock at $16.25 apiece, representing a premium of over 1% from the stock’s closing price on Wednesday.

Equity

The company announced a private placement for over four million shares of common stock at $16.25 apiece, representing a premium of over 1% from the stock’s closing price on Wednesday.


Maze Therapeutics receives positive ratings following recent IPO

Investing.com --  Maze Therapeutics  Inc (NASDAQ:MAZE) received bullish coverage from multiple analysts, with Guggenheim, JPMorgan, and TD Cowen initiating Buy or Overweight ratings on the company given its potential in genetically targeted therapies.

Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM diseases. Its pipeline includes the Compass platform, which allows it to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process to refer a variant functionalization. The company was founded by Mark Daly, Aaron D. Gitler, Stephen Elledge, Sekar Kathiresan, and Jonathan S. Weissman on August 29, 2017 and is headquartered in San Francisco, CA.

Current Price	$29.90
Prev Close	$29.12
Open	$29.16
Dividend Yield	N/A
50-Day Moving Average	$21.61
Beta	1.06
Avg. Volume	845,065.81
PE Ratio	-17.29

52-Week High	$31.93
52-Week Low	$6.71
Market Capitalization	$1.28B
EPS (Annual)	$0.0778
Price to Book	4.87
Revenue Per Employee	$1.34M
Enterprise Value/EBITDA	N/A

MAZE
Maze Therapeutics Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MAZE News

MAZEMaze Therapeutics Inc.